U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8N2O3S
Molecular Weight 212.226
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZONISAMIDE

SMILES

NS(=O)(=O)CC1=NOC2=C1C=CC=C2

InChI

InChIKey=UBQNRHZMVUUOMG-UHFFFAOYSA-N
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

HIDE SMILES / InChI
Molecular Formula C8H8N2O3S
Molecular Weight 212.226
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:49:13 UTC 2023
Edited
by admin
on Sat Dec 16 17:49:13 UTC 2023
Record UNII
459384H98V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZONISAMIDE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
ZONISAMIDE [MART.]
Common Name English
ZONISADE
Brand Name English
ZONISAMIDE [EMA EPAR]
Common Name English
AD-810
Code English
CI-912
Code English
N03AX15
Code English
1,2-BENZISOXAZOLE-3-METHANESULFONAMIDE
Systematic Name English
ZONISAMIDE [USAN]
Common Name English
ZONISAMIDE [USP MONOGRAPH]
Common Name English
ZONISAMIDE [ORANGE BOOK]
Common Name English
ZONEGRAN
Brand Name English
ZONISAMIDE [MI]
Common Name English
zonisamide [INN]
Common Name English
Zonisamide [WHO-DD]
Common Name English
ZONISAMIDE [JAN]
Common Name English
ZONISAMIDE [HSDB]
Common Name English
PD-110843
Code English
ZONISAMIDE [USP-RS]
Common Name English
ZONISAMIDE [VANDF]
Common Name English
EXCEGRAN
Brand Name English
Classification Tree Code System Code
WHO-ATC N03AX15
Created by admin on Sat Dec 16 17:49:15 UTC 2023 , Edited by admin on Sat Dec 16 17:49:15 UTC 2023
NCI_THESAURUS C264
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
NDF-RT N0000175753
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
EMA ASSESSMENT REPORTS ZONEGRAN (AUTHORIZED: EPILEPSIES, PARTIAL)
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
NDF-RT N0000008486
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
WHO-VATC QN03AX15
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
LIVERTOX NBK548809
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
Code System Code Type Description
FDA UNII
459384H98V
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
USAN
T-111
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
RS_ITEM_NUM
1725003
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
IUPHAR
7047
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
SMS_ID
100000088020
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
PUBCHEM
5734
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
MESH
C022189
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
RXCUI
39998
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID9046023
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
INN
5575
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
CAS
68291-97-4
Created by admin on Sat Dec 16 17:49:15 UTC 2023 , Edited by admin on Sat Dec 16 17:49:15 UTC 2023
PRIMARY
LACTMED
Zonisamide
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
EVMPD
SUB00187MIG
Created by admin on Sat Dec 16 17:49:15 UTC 2023 , Edited by admin on Sat Dec 16 17:49:15 UTC 2023
PRIMARY
MERCK INDEX
m11662
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY Merck Index
CHEBI
10127
Created by admin on Sat Dec 16 17:49:15 UTC 2023 , Edited by admin on Sat Dec 16 17:49:15 UTC 2023
PRIMARY
NCI_THESAURUS
C47790
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
DRUG BANK
DB00909
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
WIKIPEDIA
ZONISAMIDE
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL750
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
HSDB
7293
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
DAILYMED
459384H98V
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
DRUG CENTRAL
2872
Created by admin on Sat Dec 16 17:49:16 UTC 2023 , Edited by admin on Sat Dec 16 17:49:16 UTC 2023
PRIMARY
Related Record Type Details
SODIUM CHANNEL PROTEIN TYPE 5 SUBUNIT ALPHA
TARGET -> INHIBITOR
SODIUM CHANNEL PROTEIN TYPE 2 SUBUNIT ALPHA
TARGET -> INHIBITOR
SODIUM CHANNEL PROTEIN TYPE 4 SUBUNIT ALPHA
TARGET -> INHIBITOR
Structure of ZONISAMIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
CARBONIC ANHYDRASE 2
OFF-TARGET->INHIBITOR
Following 60 minutes preincubation, non-preincubated sample 4.64 (4.06-5.30) micromolar
Ki
VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1H
TARGET -> INHIBITOR
VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1I
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ZONISAMIDE
EXCRETED UNCHANGED
AMOUNT EXCRETED
URINE
SODIUM CHANNEL PROTEIN TYPE 1 SUBUNIT ALPHA
TARGET -> INHIBITOR
CARBONIC ANHYDRASE 1
OFF-TARGET->INHIBITOR
Non preinucabated sample
Ki
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
SODIUM CHANNEL PROTEIN TYPE 3 SUBUNIT ALPHA
TARGET -> INHIBITOR
SODIUM CHANNEL PROTEIN TYPE 9 SUBUNIT ALPHA
TARGET -> INHIBITOR
VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL SUBUNIT ALPHA-1G
TARGET -> INHIBITOR
Related Record Type Details
Structure of N-ACETYL ZONISAMIDE
METABOLITE -> PARENT
URINE
Structure of 2-SULFAMOYLACETYL PHENOL
METABOLITE -> PARENT
Structure of 2-SULFAMOYLACETYL PHENOL-O-GLUCURONIDE
METABOLITE -> PARENT
MAJOR
URINE
Related Record Type Details
Structure of 1,2-BENZISOXAZOLE-3-METHANESULFONIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of ZONISAMIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

DOSE

FED CONDITION

Tmax PHARMACOKINETIC DOSE

ORAL ADMINISTRATION

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966